Hyderabad: Hyderabad-based Biophore India Pharmaceuticals has announced that it has successfully completed the validation of Favipiravir and scaled-up its production. Favipiravir is the active pharmaceutical ingredient (API) that can be used in the finished formulation of an antiviral drug approved by the Drug Controller General of India (DCGI) for mild to moderate cases of Covid-19.
Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well. It has also received approval in Turkey in collaboration with a local Turkish partner. Additionally, the company is in talks with several Indian partners to commercialise the product in India and with Bangladesh and Egypt-based companies for its export.
Biophore chief scientific officer and founder Dr Manik Reddy Pullagurla said, “We have ensured that our Favipiravir meets the highest standards of quality. Our manufacturing facilities comply with US and EU regulations and we have stringent internal impurity controls and quality checks to ensure that. Meeting Favipiravir needs in India is our priority, and we have the capacity to scale up production to meet local requirements, without compromising on our export commitments.”.
Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA virus, the influenza virus. Apart from India and Turkey, it has already been approved for use against Covid-19 in Russia and parts of the Middle East and advanced stage trials are currently underway in other parts of the world.
Biophore CEO Dr Jagadeesh Babu Rangisetty said that the company’s favipiravir is 100 per cent Made in India and all starting materials and complex intermediates are either sourced locally or have been developed in-house for use. Biophore is also awaiting DCGI approval for a Favipiravir finished dosage form.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.